header logo image


Page 730«..1020..729730731732..740750..»

A genetic study of 200,000 veterans with anxiety points toward potential new avenues for treatment – CNN

January 12th, 2020 2:42 pm

The genome-wide association study was the "largest ever study" looking into genes that could be associated with anxiety, according to Daniel Levey, a postdoctorate associate at the Yale School of Medicine and one of the authors of the study.

Levey's research group focused on 199,611 veterans in the data that had a continuous trait for anxiety based on a diagnostic scale for Generalized Anxiety Disorder.

Although anxiety is common across the human condition, Levey said "some people experience it in a way that becomes pathological."

Generalized Anxiety Disorder can manifest often in those who've experienced trauma while waging war far from home and looking at the genetic traits of veterans it affects can help the population as a whole.

They cast a wide net and came up with a few gems

Levey said having a "very large cohort is very effective" and the Veterans Affairs program is "one of the richest resources in the world" for data linking anxiety and genetics.

He noted that the veteran's data bank is valuable because of its racial diversity. Similar large-scale studies like this have been hamstrung by too many participants coming from a similar background, oftentimes only those with European ancestry.

In this most recent study, the researchers found that veterans of European descent had five genes that could be associated with anxiety.

One of the most useful findings was an association between anxiety and a gene named MAD1L1. In previous genome-wide association studies, MAD1L1 had shown indicated vulnerability to several other psychiatric conditions, including bipolar disorder and schizophrenia.

"It keeps coming up over and over again," Levey said.

They also identified a gene connected to estrogen. Levey said that potential estrogen link was important because this veteran cohort was 90% male, and that particular hormone is often associated with women.

For African Americans, the researchers identified a gene associated with intestinal functions that was potentially linked to anxiety.

"That gene variant doesn't exist outside African populations," Levey said.

The goal is to pinpoint more targeted treatments

Results like these could lead to more specific studies on each of the genes identified to determine how exactly they might be linked to anxiety and other psychological disorders. If further scrutiny of the genes reinforces the study's conclusions, that could lead to pharmaceutical research targeting how these genes operate.

Levey said he hoped that the study could lead to even more proactive outcomes, including early genetic testing to determine someone's susceptibility to anxiety. Individuals could then receive therapy to learn positive coping and stress management techniques even before symptoms began to surface, he said.

"We're making a lot of progress in genetics into what causes these conditions and how we might approach treatment," he said.

Continue reading here:
A genetic study of 200,000 veterans with anxiety points toward potential new avenues for treatment - CNN

Read More...

Image of the Month: Nervous tissue of the fruit fly embryo – Baylor College of Medicine News

January 12th, 2020 2:42 pm

The fruit fly is a valuable animal model to unravel the genetic causes of both rare and more common human diseases. This Image of the Month presents work from Dr. Hugo Bellens lab showing in the fruit fly embryo the location of the protein schizo, which is involved in neural development.

In his laboratory at Baylor College of Medicine, Dr. Hugo Bellen and his colleagues investigate the mechanisms involved in neural development and function in the fruit fly, Drosophila melanogaster. In many instances, their approach includes developing new technologies to manipulate genes and creating the reagents to implement these techniques for most fruit fly genes.

As the Drosophila Core of the Model Organisms Screening Center of the Undiagnosed Diseases Network, the Bellen lab participates in the discovery of unknown human neurological diseases. They also study mechanisms of neurodegeneration associated with more common neurodegenerative conditions, such as Alzheimers disease, Parkinsons disease, Amyotrophic Lateral Sclerosis and Friedreich Ataxia.

Dr. Hugo Bellenis a professor at Baylor College of Medicine, an investigator at theHoward Hughes Medical Instituteand a member of theJan and Dan Duncan Neurological Research InstituteatTexas Childrens Hospital.

By Ana Mara Rodrguez, Ph.D.

Follow this link:
Image of the Month: Nervous tissue of the fruit fly embryo - Baylor College of Medicine News

Read More...

Global Biotechnology Reagents Market 2019-2023 | Evolving Opportunities with Agilent Technologies and BD | Technavio – Business Wire

January 12th, 2020 2:41 pm

LONDON--(BUSINESS WIRE)--Technavio has been monitoring the global biotechnology reagents market since 2014 and the market is poised to grow by USD 37.98 billion during the period 2019-2023, progressing at a CAGR of almost 9% during the forecast period. Request free sample pages

Read the 136-page report with TOC on Biotechnology Reagents Market Analysis Report by Technology (Chromatography, In-vitro diagnostics, Polymerase chain reaction, Cell culture, and Others), Geography (Americas, APAC, and EMEA), and the Segment Forecasts, 2019-2023.

https://www.technavio.com/report/global-biotechnology-reagents-market-industry-analysis

The market is driven by the high usage of biotechnology reagents in diagnostic and therapeutic applications. In addition, increasing stem cell and biomedical research is anticipated to boost the growth of the biotechnology reagents market.

The market is observing a significant rise in the demand for biotechnology reagents in diagnostic and therapeutic applications. This is due to advances in technologies such as cell structure, recombinant DNA and biotherapeutics, and emerging neurosciences and proteomics disciplines. The demand for ready-to-use reagents is also growing significantly in clinical laboratories and hospitals as they ensure minimal calculation, dilution, and pipetting errors. They also help reduce the duration of the diagnostic procedure and prevent sample contamination. These factors are crucial in driving the growth of the global biotechnology reagents market.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Major Five Biotechnology Reagents Market Companies:

Agilent Technologies

Agilent Technologies operates the business through segments such as Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The company offers a wide range of biotechnology reagents. Some of the key offerings of the company include Erythrocyte-Lysing Reagent without Fixative, EasyLyse, Erythrocyte-Lysing Reagent, Uti-Lyse, and miRNA qPCR Detection Reagents.

BD

BD operates the business through segments such as BD Medical, BD Life Sciences, and BD Interventional. The company offers a wide range of biotechnology reagents. BD OptiBuild, CD20 PE Clone L27 (ASR), and CD2 APC Clone L303.1 (also known as L303) (ASR) are some of its key offerings.

Bio-Rad Laboratories

Bio-Rad Laboratories operates the business through segments such as life science, clinical diagnostics, and others. iScript RT-qPCR Sample Preparation Reagent, Kovacs Reagent, Anti-D Reference Reagent are some of its key offerings.

GENERAL ELECTRIC

GENERAL ELECTRIC operates the business across various segments such as power, renewable energy, oil & gas, aviation, healthcare, transportation, lighting, and capital. The company offers a wide range of biotechnology reagents. Some of the key offerings of the company include Amersham ECL Detection Reagents, CDP-Star Detection Reagents, and PDEA Thiol Coupling Reagent.

Merck KGaA

Merck KGaA operates the business across segments such as healthcare, life science, and performance materials. The company offers a wide range of biotechnology reagents. Solvents for Liquid Chromatography LiChrosolv, Reagents for Acylation, and Silylation Derivatization Reagent are some of the key offerings of the company.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio's SUBSCRIPTION platform

Technavio has segmented the biotechnology reagents market based on the technology and region.

Biotechnology Reagents Technology Outlook (Revenue, USD Billion, 2019 - 2023)

Biotechnology Reagents Regional Outlook (Revenue, USD Billion, 2019 - 2023)

Technavios sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report

Related Reports on Healthcare include:

Global Affinity Chromatography Reagents Market Global affinity chromatography reagents market by end-users (pharmaceutical and biotechnology industry, food and beverage industry, cosmetic industry, and others) and geography (Asia, Europe, North America, and ROW).

Global Molecular Biology Enzymes, Kits, and Reagents Market Global molecular biology enzymes, kits, and reagents market by end-users (biotechnology and pharmaceutical companies, hospitals and diagnostic centers, and academic institutes and research organizations) and geography (Asia, Europe, North America, and ROW).

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at media@technavio.com

Read more from the original source:
Global Biotechnology Reagents Market 2019-2023 | Evolving Opportunities with Agilent Technologies and BD | Technavio - Business Wire

Read More...

BIRAC Supported Biotechnology Park And Incubation Centre In Rajasthan Soon – IndianWeb2.com

January 12th, 2020 2:41 pm

A biotechnology park and incubation centre will be set up in Rajasthan for which a Memorandum of Understanding (MoU) will be signed between the Centre and the state government, Union Secretary, Department of Biotechnology, Renu Swaroop said on Friday.

The park and incubation centre will provide an opportunity to conduct research in the field of biotechnology and employment to the youth, she said.

Swaroop was addressing the State Biotech Cohort Meeting, which was attended by vice chancellors, directors and deans of all universities having biotechnology courses, representatives from institutes conducting research in biotechnology and start-ups associated with it.

Swaroop said the Centre will provide full support and assistance to promote biotechnology in Rajasthan.

The biotechnology park and incubation centre will be set up with the support of Biotechnology Industry Research Assistance Council (BIRAC).

She said utility of biotechnology is increasing in every field, including health, agriculture and agriculture production, industry, edible food, among others. There is a need to promote biotechnology, and encouraging it will give pace to industrial development and research, she added.

Rajasthan Department of Science and Technology Secretary Mugdha Sinha said bio-informatics, biomedical engineering and nano medicine will be encouraged in the state.

The Rajasthan government recently launched Nirogi Rajasthan (Healthy Rajasthan) campaign and all possible assistance through bio-informatics will be provided to strengthen it, she added.

Biotechnology ecosystem and start-ups will be improved in the state with the help from Centre, she said. PTI AG

Like this content? Sign up for our daily newsletter to get latest updates.

See the article here:
BIRAC Supported Biotechnology Park And Incubation Centre In Rajasthan Soon - IndianWeb2.com

Read More...

Biotechnologists urged to explain their work’s significance – The National

January 12th, 2020 2:41 pm

A LEADING scientist, writer and broadcaster will tell a conference in Glasgow that start-ups in industrial biotechnology (IB) have to get out and tell people what they are doing.

Writer and broadcaster Vivienne Parry will tell the annual conference of the Industrial Biotechnology Innovation Centre (IBioIC) that scientists can sometimes struggle to present the significance of the work they undertake to help save the planet.

She is one of the keynote speakers at next months conference, which will see more than 450 delegates and a host of companies exhibiting their smart solutions to a global audience.

READ MORE:Scottish Government's broadband pledge exceeds superfast

Parry, a scientist by training, is head of engagement at Genomics England and a member of the UK Research and Innovation Board. She previously had a role on the BBCs Tomorrows World programme.

Writer and broadcaster Vivienne Parry.

She said: Industrial biotechnology start-ups need to get out and tell people what they are doing, quickly demonstrating the solution to a problem.

Scientists can sometimes struggle to communicate to policy makers and the public the significance of what they are doing to save the planet.

Keep it simple and show the real value in your product and the positive impact it can make to everyday life and the environment. When I listen to someone presenting their concepts, I want them to excite me about the potential of their product in a way that is not hyped, but is really clear.

Biotechnology is the science of using plant-based and waste resources to produce or process materials, chemicals and energy, and offers green and sustainable alternatives to fossil fuels in everything from energy to medicines and food packaging.

To date, IBioIC has overseen the doubling of IB in Scotland to more than 350 million and supported more than 130 companies, 50 research projects and 18 Scottish universities and research institutes.

The IBioIC conference will see global experts share their knowledge, challenges, opportunities and best practice, and will again highlight Scotlands capabilities in driving the bio-based economy.

The recent BioCity UK Life Science Start-Up Report revealed Scotland is the leading UK centre for environmental and agricultural biotech start-ups, with positively disproportionate growth to the rest of the UK which is great, said Mark Bustard, commercial director at IBioIC.

READ MORE:Michael Fry's predictions for the advances of the coming decade

But to truly succeed, a change in mindset from great science to

successful manufacturing is needed if they are to capitalise on their innovations. The move to manufacturing generally happens with significant capital investment which they secure from being able to demonstrate robust processes clearly to prospective backers.

Scotland has a national plan for IB and, as a nation, it is rich in natural resources. We just need to capitalise on it in a similar way the Nordic countries have.

Bustard went on to list some of Scotlands success stories in biotech.

There is a growing appreciation and support for the role bio-based industries have in tackling the climate change emergency and creating a circular economy to meet the Governments net zero carbon targets by 2045.

Companies like ScotBio, CelluComp and Celtic Renewables are all fantastic examples of award-winning organisations who are doing just that by driving science to generate and make products. They are creating workforces of innovators who are interested in manufacturing.

Scotland has an eco-system that supports and develops IB talent and IBioICs scale-up facilities provide a platform for academics and entrepreneurs to accelerate growth and demonstrate proof of concept.

View post:
Biotechnologists urged to explain their work's significance - The National

Read More...

Analysts Anticipate Unity Biotechnology Inc (NASDAQ:UBX) Will Announce Earnings of -$0.54 Per Share – Riverton Roll

January 12th, 2020 2:41 pm

Wall Street analysts expect Unity Biotechnology Inc (NASDAQ:UBX) to report ($0.54) earnings per share (EPS) for the current quarter, according to Zacks. Zero analysts have issued estimates for Unity Biotechnologys earnings. Unity Biotechnology reported earnings of ($0.48) per share in the same quarter last year, which indicates a negative year over year growth rate of 12.5%. The business is scheduled to report its next quarterly earnings report on Wednesday, March 4th.

On average, analysts expect that Unity Biotechnology will report full-year earnings of ($1.99) per share for the current financial year, with EPS estimates ranging from ($2.05) to ($1.93). For the next financial year, analysts expect that the business will post earnings of ($2.17) per share, with EPS estimates ranging from ($2.41) to ($1.93). Zacks Investment Researchs EPS averages are a mean average based on a survey of sell-side research firms that that provide coverage for Unity Biotechnology.

Unity Biotechnology (NASDAQ:UBX) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.54) earnings per share for the quarter, missing the Thomson Reuters consensus estimate of ($0.49) by ($0.05).

UBX has been the subject of a number of research analyst reports. Mizuho restated a buy rating and set a $33.00 price objective on shares of Unity Biotechnology in a report on Monday, November 18th. ValuEngine upgraded shares of Unity Biotechnology from a buy rating to a strong-buy rating in a report on Friday. Cantor Fitzgerald restated an overweight rating and set a $20.00 price objective on shares of Unity Biotechnology in a report on Thursday, December 12th. Finally, Zacks Investment Research downgraded shares of Unity Biotechnology from a buy rating to a hold rating in a report on Wednesday, December 18th. One research analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. Unity Biotechnology presently has an average rating of Buy and a consensus price target of $18.81.

Shares of UBX stock opened at $7.10 on Thursday. The firm has a 50-day moving average of $7.38 and a 200-day moving average of $7.21. Unity Biotechnology has a one year low of $5.61 and a one year high of $16.87.

A number of large investors have recently modified their holdings of the business. Bank of Montreal Can boosted its position in Unity Biotechnology by 164,400.0% during the second quarter. Bank of Montreal Can now owns 4,935 shares of the companys stock worth $47,000 after purchasing an additional 4,932 shares during the period. Aperio Group LLC bought a new position in Unity Biotechnology during the second quarter worth about $50,000. Northern Trust Corp boosted its position in Unity Biotechnology by 2.4% during the second quarter. Northern Trust Corp now owns 242,690 shares of the companys stock worth $2,306,000 after purchasing an additional 5,756 shares during the period. Bank of New York Mellon Corp boosted its position in Unity Biotechnology by 9.6% during the second quarter. Bank of New York Mellon Corp now owns 69,516 shares of the companys stock worth $660,000 after purchasing an additional 6,112 shares during the period. Finally, Tower Research Capital LLC TRC bought a new position in Unity Biotechnology during the third quarter worth about $45,000. Hedge funds and other institutional investors own 35.56% of the companys stock.

About Unity Biotechnology

Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to extend human health span. The company's lead drug candidates include UBX0101 that is in Phase 1 clinical study for musculoskeletal disease; and UBX1967 for ophthalmologic diseases. It is also developing programs in pulmonary disorders.

Recommended Story: Understanding Analyst Recommendations

Get a free copy of the Zacks research report on Unity Biotechnology (UBX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Unity Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unity Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.

View post:
Analysts Anticipate Unity Biotechnology Inc (NASDAQ:UBX) Will Announce Earnings of -$0.54 Per Share - Riverton Roll

Read More...

Merck and 4SC collaborate in immunooncology – European Biotechnology

January 12th, 2020 2:41 pm

4SC AG and Merck KgaA have signed a supply agreement to start clinical tests of Mercks checkpoint blocker avelumab plus 4SCs HDAC I blocker domatinostat.

Under the agreement, 4SC AG will sponsor clinical testing of a combination of its oral class I histone deacetylase (HDAC) blocker domatinostat (HDAC inhibitor) and Mercks/Pfizers PD-L1 checkpoint inhibitor avelumab in patients with Merkel cell carcinoma (MCC).

MCC is an orphan, highly immunogenic type of non-melanoma skin cancer. In 2017, avelumab got FDA and EU approval for metastatic MCC. However, about 50% of this patient population do not respond, progress or relapse when treated with avelumab monotherapy. Domatinostatis an orally administered small molecule class I selective HDAC inhibitor which preclinically boosted the anti-tumour immune response, positively affected the tumour microenvironment by facilitating the infiltration of immune cells into the tumour.

In Phase I trials, domatinostat was well tolerated from patietns with several types of advanced hematologic cancers and 4SC observed positive signs of anti-tumour efficacy. To elucidate the potential of domatinostat as a booster of the immune response to tumours, 4SC not only conducts Phase ib/II combination studies with avelumab in MCC but also with MSDs PD1 blocker pembrolizumab in patients with advanced-stage melanoma and with BMS nivolumab.

4SC also conducts a second Phase II study of domatinostat in combination with the avelumab in patients with advanced-stage microsatellite-stable gastrointestinal cancer at The Royal Marsden NHS Foundation Trust in London.

Read the rest here:
Merck and 4SC collaborate in immunooncology - European Biotechnology

Read More...

Agricultural Biotechnology Market Boosting the Growth Worldwide: Market Dynamics And Trends, Efficiencies Forecast 2024 – ReportsPioneer

January 12th, 2020 2:41 pm

Agricultural Biotechnology Market explores effective study on varied sections of Industry like opportunities, size, growth, technology, demand and trend of high leading players. It also provides market key statistics on the status of manufacturers, a valuable source of guidance, direction for companies and individuals interested in the industry. This marketresearchreport looks into and analyzes the Global Agricultural Biotechnology Market and illustrates a comprehensive evaluation of its evolution and its specifications. Another aspect that was considered is the cost analysis of the main products dominant in the Global Market considering the profit margin of the manufacturers.

Biotechnology is a type of scientific technique used in various fields to make improvements & add modified technological advancement. Agricultural biotechnology will include the techniques used to enhance crop productivity & efficiency. It helps farmers to make crop production at cheaper & reasonable rate by using advanced innovative technology. Agricultural biotechnology can be utilized to protect crops from destructive diseases. It is mainly used to modify the genetic sequence of crops and also known as transgenic or genetically modified crops.

Get Free PDF Sample Pages Of Agricultural Biotechnology Market Report: https://www.advancemarketanalytics.com/sample-report/3758-global-agricultural-biotechnology-market

Major Key Players in This Report Include,

Adama Agricultural Solutions Ltd. (China), BASF SE (Germany), Bayer AG (Germany), Certis USA LLC (United States), Dowdupont Inc. (United States), Evogene Ltd. (Israel), Global Bio-Chem Technology Group Company Limited (Hong Kong) and KWS SAAT SE (Germany)

This research is categorized differently considering the various aspects of this market. It also evaluates the current situation and the future of the market by using the forecast horizon. The forecast is analyzed based on the volume and revenue of this market. The tools used for analyzing the Global Agricultural Biotechnology Market research report include SWOT analysis.

The regional analysis of Global Agricultural Biotechnology Market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the leading region across the world. Whereas, owing to rising no. of research activities in countries such as China, India, and Japan, Asia Pacific region is also expected to exhibit higher growth rate the forecast period 2019-2025.

For Early Buyers | Get Up to 20% Discount on This Premium Report: https://www.advancemarketanalytics.com/request-discount/3758-global-agricultural-biotechnology-market

The Global Agricultural Biotechnology Market in terms of investment potential in various segments of the market and illustrate the feasibility of explaining the feasibility of a new project to be successful in the near future. The core segmentation of the global market is based on product types, SMEs and large corporations. The report also collects data for each major player in the market based on current company profiles, gross margins, sales prices, sales revenue, sales volume, photos, product specifications and up-to-date contact information.

Table of Content

Global Agricultural Biotechnology Market Research Report

Chapter 1 Global Agricultural Biotechnology Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Productions, Revenue (Value) by Region

Chapter 5 Global Supplies (Production), Consumption, Export, Import by Regions

Chapter 6 Global Productions, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Agricultural Biotechnology Market Forecast

Get More Information & Customization: https://www.advancemarketanalytics.com/enquiry-before-buy/3758-global-agricultural-biotechnology-market

Contact Us:

Craig Francis (PR & Marketing Manager)AMA Research & Media LLPUnit No. 429, Parsonage Road Edison, NJNew Jersey USA 08837Phone: +1 (206) 317 1218[emailprotected]

The rest is here:
Agricultural Biotechnology Market Boosting the Growth Worldwide: Market Dynamics And Trends, Efficiencies Forecast 2024 - ReportsPioneer

Read More...

Gene editing could revolutionize the food industry, but it’ll have to fight the PR war GMO foods lost – CBC.ca

January 12th, 2020 2:41 pm

In his greenhouse at the Cold SpringHarbor Laboratory in Long Island, N.Y., plant geneticist Zach Lippman is growing cherry tomatoes.

But they don't look like the ones that most people grow in their gardens and greenhouses.

Lippman's tomatoes have shorter stemsand the fruit is more tightly clustered, looking more like grapes.

"With gene editing, we now have the ability to fine-tune at will," he said. "So instead of having black or white, small fruit [or] big fruit, you can have everything in between."

Lippman used CRISPR arevolutionarygene-editing tool that can quickly and precisely edit DNA to tweak three of the plant's genes, and make them suitable for large-scale urban agriculture for the first time.

With CRISPR, researchers can precisely target and cut any kind of genetic material. Don't want your mushrooms to turn brown after a few days? Remove the gene that causes thatand problem solved.

There's a lot of excitement about the introduction of gene-edited products into the Canadian food system over the next few years, but a lot of trepidation as well.

The food industry's last foray into genetic engineering genetically modified organisms (GMOs) in the 1990s was a financial success. But the practice is an ongoing public relations nightmare, as many Canadians remain wary of products critics have labelled "Frankenfoods."

Currently, the only gene-edited product commercially available is a soybean oil being used by a restaurant chain in the American Midwest for cooking and salad dressings. It has a longer shelf life than other cooking oils and produces less saturated fat and no trans fat.

Ian Affleck, vice-president of plant biotechnology at CropLife Canada, a trade association that represents Canadian manufacturers of pesticides and plant-breeding products, estimates the soybean oil might be in Canada in a year or two, followed by some altered fruits and vegetables.

Even then, he said, supplies will likely be limited while farmers and food companies determine if consumers will embrace genetically edited food.

All the major health organizations in the world, including Health Canada, have concluded that eating GMO foods does not pose eithershort or long-term health risks.

According to the World Health Organization, GMO goods currently approved for the market "have passed safety assessments and are not likely to present risks for human health."

But Canadians remain stubbornly unconvinced even though about 90 per cent of the corn, soybeansand canola grown in Canada is genetically modified, as is almost all of the processed food we consume.

A 2018 pollby market research company Statista found only 37 per cent of people surveyed strongly or somewhat strongly agreed that GMOs were safe to eat, while 34 per cent strongly or somewhat strongly disagreed.

Industry representatives now say they spent too much time marketing their GMOproducts to farmersand not enough time communicating the benefitsto consumers.

"We spoke to two per cent of the population, who are those who farm," said Affleck. "And those who opposed the technology spoke to the other 98 per cent of the population."

"We thought it was just another transition in plant breeding," recalled Stuart Smyth, who holds the University of Saskatchewan's industry-funded research chair in agri-food innovation. "Nobody expected the environmental groups to develop into a political opposition."

With gene-edited foods, Smyth believes the industry needs to focus on public education to counteract what he calls the "propaganda" that will be coming from the other side.

Gene-edited foods will differ from GMOs in one important respect.

When foods are genetically modified, foreign genes are often added to an existing genome. If you want a vegetable to grow better in cold weather, you could add a gene from a fish that lives in icy water.That's what earned GMO products the "Frankenfoods" moniker.

With gene-editing tools like CRISPR, genes can be cut out, or "turned off," but nothing new is added to the genome.

Lucy Sharratt, co-ordinator of the Canadian Biotechnology Action Network, isn't convinced there's a significant difference.

"The new techniques of gene editing are clearly techniques of genetic engineering," she said. "They are all invasive methods of changing a genome directly at the molecular level.

"While we can produce organisms with new traits, that doesn't mean we know exactly all of what we've done to that organism. There can be many unintended effects," Sharratt further argued.

Unlike GMOs, which require extensive regulatory approval before going to market, gene-edited foods will likely appear without undergoing a risk assessment by Canadian regulators.

Health Canada doesn't require safety testing for new products if it determines those products aren't introducing "novel traits" into the food system. Since it considers gene editing to be an extension of traditional plant breeding, no stamp of approval will be necessary.

That concerns Jennifer Kuzma, co-director of the Genetic Engineering and Society Center at North Carolina State University, whothinks gene-edited products should be tracked and monitored "for those low-level health effects that some products might be contributing to."

Sharratt is also skeptical that gene editing will produce the benefits its supporters claim, pointing to "a biotech industry that has oversold technology and made all kinds of broad promises for the use of genetic engineering that didn't come to pass." Things like reduced pesticide use and greater drought resistance, for example.

Kuzma agrees that GMO researchers have sometimes been guilty of "perhaps overstating the promise of the technology and understating potential risk."But she believes those involved in developing gene-editing techniques want to avoid repeating the mistakes of the past.

"They have a really sincere desire to be more open and transparent in the ways that they communicate and in the sharing of information," she said. "They do realize that the first generation of genetic engineering did not go so well from a public confidence perspective."

The GMO food industry has fiercely opposed one of the most obvious methods to boost public confidence: mandatory labelling, even as a 2018 survey from Dalhousie University showed an overwhelming majority of Canadians support it.

Sixty-four countries require mandatory labelling for GMO products. Canada is not one of them.

There are no plans to require mandatory labelling of gene-edited foods, either.

Jonathan Latham, executive director of the Bioscience Resource Project, a New York-based non-profit organization that researches genetic engineering, thinks that's a mistake.

"If you want people to make informed decisions and you want them to make that in a democratic fashion, then the more information you give them, the better," he said. "And so to deny people information about the content of their food is to violate a very basic democratic right."

Lathamalso believes that not labelling genetically engineered productsincreases consumer skepticism.

"[Consumers] don't really understand why, if a company wants to produce a product and advertise it and tell everybody how good it is, why they shouldn't also want to label it," he said.

Sharratt would like to see Canada adopt the approach taken by the European Court of Justice, which ruled in 2018 that gene-edited foods must undergo the same testing as GMOs before being allowed on grocery store shelves.

Lippman doesn't believe that will happen. In fact, he thinks the potential of gene-edited foods is so great that the public will demand even greater access to suchproducts.

"People will start to be educated and see that there's nothing harmful about it. It's completely fine. And then the only issue sticking out there will be whether we're over-promising.That'll be it."

Click 'listen' above to hear Ira Basen's documentary, The Splice of Life.

Read the original here:
Gene editing could revolutionize the food industry, but it'll have to fight the PR war GMO foods lost - CBC.ca

Read More...

Should You Be Impressed By Universal Vision Biotechnology Co., Ltd.s (GTSM:3218) ROE? – Simply Wall St

January 12th, 2020 2:41 pm

One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will work through how we can use Return On Equity (ROE) to better understand a business. Well use ROE to examine Universal Vision Biotechnology Co., Ltd. (GTSM:3218), by way of a worked example.

Over the last twelve months Universal Vision Biotechnology has recorded a ROE of 11%. That means that for every NT$1 worth of shareholders equity, it generated NT$0.11 in profit.

Check out our latest analysis for Universal Vision Biotechnology

The formula for return on equity is:

Return on Equity = Net Profit (from continuing operations) Shareholders Equity

Or for Universal Vision Biotechnology:

11% = NT$183m NT$1.6b (Based on the trailing twelve months to September 2019.)

Most know that net profit is the total earnings after all expenses, but the concept of shareholders equity is a little more complicated. It is the capital paid in by shareholders, plus any retained earnings. Shareholders equity can be calculated by subtracting the total liabilities of the company from the total assets of the company.

ROE looks at the amount a company earns relative to the money it has kept within the business. The return is the yearly profit. That means that the higher the ROE, the more profitable the company is. So, all else equal, investors should like a high ROE. That means it can be interesting to compare the ROE of different companies.

One simple way to determine if a company has a good return on equity is to compare it to the average for its industry. The limitation of this approach is that some companies are quite different from others, even within the same industry classification. Pleasingly, Universal Vision Biotechnology has a superior ROE than the average (8.8%) company in the Healthcare industry.

That is a good sign. We think a high ROE, alone, is usually enough to justify further research into a company. For example you might check if insiders are buying shares.

Companies usually need to invest money to grow their profits. That cash can come from issuing shares, retained earnings, or debt. In the first two cases, the ROE will capture this use of capital to grow. In the latter case, the debt required for growth will boost returns, but will not impact the shareholders equity. In this manner the use of debt will boost ROE, even though the core economics of the business stay the same.

While Universal Vision Biotechnology does have a tiny amount of debt, with debt to equity of just 0.051, we think the use of debt is very modest. The fact that it achieved a fairly good ROE with only modest debt suggests the business might be worth putting on your watchlist. Judicious use of debt to improve returns can certainly be a good thing, although it does elevate risk slightly and reduce future optionality.

Return on equity is useful for comparing the quality of different businesses. In my book the highest quality companies have high return on equity, despite low debt. If two companies have around the same level of debt to equity, and one has a higher ROE, Id generally prefer the one with higher ROE.

But ROE is just one piece of a bigger puzzle, since high quality businesses often trade on high multiples of earnings. Profit growth rates, versus the expectations reflected in the price of the stock, are a particularly important to consider. Check the past profit growth by Universal Vision Biotechnology by looking at this visualization of past earnings, revenue and cash flow.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

View post:
Should You Be Impressed By Universal Vision Biotechnology Co., Ltd.s (GTSM:3218) ROE? - Simply Wall St

Read More...

This Week’s Awesome Tech Stories From Around the Web (Through January 11) – Singularity Hub

January 11th, 2020 5:49 pm

ARTIFICIAL INTELLIGENCE

Can an AI Be an Inventor? Not Yet.Angela Chen | MIT Technology Review[Ryan Abbott] believes there will be more and more cases where AI should be considered a genuine inventor and that the law needs to be ready. At stake in this discussion is the future of innovation, he says. Not allowing AI be recognized as an inventor is not only morally problematic, he says, but will lead to unintended consequences.

The Superpowers of Super-Thin MaterialsAmos Zeeberg | The New York TimesAs researchers like [Toms Palacios] see it, two-dimensional materials will be the linchpin of the internet of everything. They will be painted on bridges and form the sensors to watch for strain and cracks. They will cover windows with transparent layers that become visible only when information is displayed. Increasingly, the future looks flat.

Panasonics VR Glasses Support HDR and Look Pretty SteampunkSam Byford | The VergeThe problem with VR headsets is that they still all look like VR headsetsglorified ski goggles that shut you off from the world. my main takeaway from the demo was that hey, turns out its possible to make VR glasses that are both better qualityand with a better form factor.

Why the Quantum Internet Should Be Built in SpaceEmerging Technology From the arXiv | MIT Technology Review[Sumeet Khatri and colleagues have] studied the various ways a quantum internet could be built and say the most cost-effective approach is to create a constellation of quantum-enabled satellites capable of continuously broadcasting entangled photons to the ground. In other words, the quantum internet should be space-based.

The Gene Drive Dilemma: We Can Alter Entire Species, but Should We?Jennifer Kahn | The New York Times MagazineA new genetic engineering technology could help eliminate malaria and stave off extinctionsif humanity decides to unleash it.

Bots Are Destroying Political Discourse as We Know ItBruce Schneier | The AtlanticSoon, AI-driven personas will be able to write personalized letters to newspapers and elected officials, submit individual comments to public rule-making processes, and intelligently debate political issues on social media. They will be replicated in the millions and engage on the issues around the clock, sending billions of messages, long and short. Putting all this together, theyll be able to drown out any actual debate on the internet.

Image Credit: Karlis Reimanis /Unsplash

Continued here:
This Week's Awesome Tech Stories From Around the Web (Through January 11) - Singularity Hub

Read More...

Rural broadband and regenerative ag make waves in subcommittee hearing | 2020-01-09 – Agri-Pulse

January 11th, 2020 5:49 pm

Agricultural practices have the potential to address climate change by sequestering carbon,witnesses told a Housesubcommittee Thursday at a hearing focused on regenerative agriculture and ag technology.

David Potere, head of GeoInnovation at Indigo Agriculture,outlinedhow his company is creating a new market for a different type of crop: carbon. The company, which was founded in 2014, has begun an initiative to sequester 1 trillion tons of atmospheric carbon dioxide in farmland around the world, and through Indigo Carbon is offering farmers the opportunity to get paid for increasing the carbon content of their soil.

Bringing farmers into the solution can be a definitive part of the solution for climate change because of the potential of ag soils to absorb carbon, Potere told members of the House Innovation and Workforce Development Subcommittee.

Potere pointed totheEnergy Improvement and Extension Act of 2008, which contains a provision allowing oil companies to receive a tax incentive for carbon sequestration when they pull oil out of the ground. The way the act is currently written, farmers don't get the same incentive.

If there is broad bipartisan support for federal policy that incentivizes corporate, industrial and energy producers to sequester carbon, why cant the same support be there when farmers try and do the same?Potere said.

When asked about other ways growers can employ ag technology to make their farms more sustainable, witnesses offered a variety of suggestions.

Roberto Meza, co-founder of Emerald Gardens Microgreens in Bennett, Colo., touted the importance of channeling funding into regenerative agriculture practices to help develop innovative models for producing food.

Interested in more climate changecoverage and insights? Receive a free month of Agri-Pulse or Agri-Pulse West by clickinghere.

Kevin France, president and CEO of SWIIM Systems in Denver,said instead of asking the government to create somethingnew, it should make programssuch as the Environmental Quality Incentives Program more accessible to farmers.

Douglas Jackson-Smith, professor and assistant director of the school of environment and natural resources at Ohio State University, brought up the missed opportunity and regulatory hurdles surroundinggenetic engineering. He said there are many technologies that could benefit farmers and consumers but havent hadthe opportunity to enter the marketplace because of the current regulatory process set in place on genetic engineering.

Witnesses and members of Congress also used the occasion to call for improved rural connectivity. Subcommittee chairman Jason Crow, D-Colo., called connectivitythe backbone of ag tech," noting the ability ofbroadband to makeit possible for farmers to aggregate and analyze data in real time. He emphasized the need forgreater deployment of high-speed internet in rural communities to help ag technology thrive.

Potere commented on the impact rural broadband access has had on his company, sayingIndigo has had tobuildmobile technology that is resilient to the lack of internet connectivity. Creating this technology for farmers has required Indigo to increase itsdevelopment cost, something Potere said puts unnecessary financialpressure on the company, especiallywhen a simple solution such as rural broadband already exists.Farmers, he said, just lack access to it.

For more news, go to http://www.Agri-Pulse.com.

Read more:
Rural broadband and regenerative ag make waves in subcommittee hearing | 2020-01-09 - Agri-Pulse

Read More...

Bayer and Azitra Partner to Harness the Human Skin Microbiome as a Source for New Natural Skin Care Products for Sensitive and Eczema-Prone Skin -…

January 11th, 2020 5:49 pm

LEVERKUSEN, Germany & FARMINGTON, Conn.--(BUSINESS WIRE)--Bayer and Azitra Inc., a clinical-stage medical dermatology biotech company, today announced a joint development agreement to collaborate in the identification and characterization of skin microbiome bacteria. The partnership will leverage Azitras proprietary panel of Staphylococcus epidermidis strains to identify potential candidates for the treatment of adverse skin conditions and diseases. Based on the results of the research partnership, Bayer plans to develop selected Staphylococcus epidermidis strains into new natural skin care products under a future License Agreement. Prospective areas of application include medicated skin care products for sensitive, eczema-prone skin as well as therapeutic products for skin diseases such as atopic dermatitis.

Recent scientific publications suggest that microorganisms such as bacteria and especially skin-friendly bacteria, commonly referred to as skin microbiome, can significantly contribute to the protection of the skin from hostile invasions. Additional positive effects include supporting the recovery from skin diseases such as atopic dermatitis, acne, and rosacea, and may also accelerate wound healing.

The skin microbiome offers a promising platform for the development and commercialization of natural skin care products more and more people are looking for. As Bayer is committed to the development of science-based consumer health products through our own research as well as external partnerships, were delighted to collaborate with Azitra. The company has already demonstrated tolerability of a selected Staphylococcus epidermidis strain in healthy volunteers and is now planning to start the clinical demonstration of efficacy, Heiko Schipper, Member of the Board of Management of Bayer AG and President of Bayer Consumer Health, comments on the new partnership.

Bayer, a global leader in innovative and trusted skincare solutions, will actively contribute to the research collaboration by providing suitable topical formulations that are able to maintain Staphylococcus epidermidis viability while showing excellent skin compatibility and sensorial performance.

"We are strongly committed to the potential of the microbiome to provide significant benefits for improved skin health and appearance and by working together with Bayer I am confident we can deliver on the promise of this technology," states Richard Andrews, President and CEO of Azitra.

Azitras versatile platform technology offers further screening options for beneficial strains appropriate for the treatment of dermatological diseases such as atopic dermatitis, acne or psoriasis. In addition, Bayer will review the use of Azitras genetically modified bacteria in Dermatology and other Consumer Health areas such as Nutritionals and Digestive Health.

About Azitra

Azitra, Inc. is a clinical-stage medical dermatology company that combines the power of the microbiome with cutting-edge genetic engineering to treat skin disease. The company was founded in 2014 by scientists from Yale University and works with world-leading scientists in dermatology, microbiology, and genetic engineering to advance its pharmaceutical programs to treat cancer therapy associated skin rashes, targeted orphan indications and atopic dermatitis.Learn more at http://www.azitrainc.com

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2018, the Group employed around 117,000 people and had sales of 39.6 billion euros. Capital expenditures amounted to 2.6 billion euros, R&D expenses to 5.2 billion euros. For more information, go to http://www.bayer.com.

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayers public reports which are available on the Bayer website at http://www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Read more from the original source:
Bayer and Azitra Partner to Harness the Human Skin Microbiome as a Source for New Natural Skin Care Products for Sensitive and Eczema-Prone Skin -...

Read More...

Acepodia Announces FDA Clearance of IND for its NK Cell Therapy Drug Candidate ACE1702 to Treat Patients with HER2-expressing Solid Tumors |…

January 11th, 2020 5:49 pm

DetailsCategory: AntibodiesPublished on Thursday, 09 January 2020 19:01Hits: 627

ACE1702 is a potential off-the-shelf cell therapy developed using Acepodias Antibody-Cell Conjugation technology

SAN FRANCISCO, CA, USA and TAIPEI, Taiwan I January 09, 2020 I Acepodia, a biotechnology company developing cancer immunotherapy based on its novel ACC (Antibody Cell-Conjugation) technology platform, today announced it has received clearance of its Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) to initiate a Phase 1 clinical study of its natural killer (NK) cell therapy and lead drug candidate ACE1702 in patients with HER2-expressing solid tumors.

The FDAs clearance of our IND for ACE1702 is a major milestone for Acepodia that represents an important initial validation of our ACC platform, which can link any antibody, including those that have already proven effective in targeting tumors, to proprietary off-the-shelf natural killer cell line (oNK cells) without the need for genetic engineering, said Sonny Hsiao, Ph.D., chief executive officer of Acepodia, and the inventor of ACC while at University of California, Berkeley. This novel approach allows us to circumvent the complexity and the limitations associated with CAR-T and traditional NK based cell therapies. ACC significantly improves manufacturing costs and has the potential to generate a cost-effective cancer treatment that can deliver increased benefit to patients. We look forward to advancing ACE1702 into its first clinical trial.

About ACE1702ACE1702 is Acepodias lead clinical product candidate developed from the Companys proprietary ACC platform. It targets human HER2-expressing solidtumors using anti-HER2 antibody conjugated oNK cells. ACE1702 has demonstrated enhanced tumor cellkilling activities both in vitro and in vivo, while maintaining a favorable safety profile in GLPtoxicology studies. In preclinical studies, ACE1702 has shown enhanced tumor-killing activities against HER2 IHC 1+, 2+ and 3+ human cancer cells.

About Acepodia Acepodia is a privately held US-Taiwan biotechnology company committed to developing safe, effective, and affordable immunotherapeutic medicines targeting diseases with significant unmet medical needs, with a primary focus on oncology. Acepodias proprietary ACC (Antibody Cell-Conjugation) technology platform links tumor targeting antibodies to the surface of a novel and proprietary human NK cell line that have been specifically selected for their potent antitumor activity. The ACC technology can be seamlessly combined with currently available antibodies allowing for the rapid development of new targeted therapies in multiple indications, without the need for genetic engineering.

SOURCE: Acepodia

Read more here:
Acepodia Announces FDA Clearance of IND for its NK Cell Therapy Drug Candidate ACE1702 to Treat Patients with HER2-expressing Solid Tumors |...

Read More...

SAB Biotherapeutics Announces Research Collaboration With CSL Behring – Business Wire

January 11th, 2020 5:49 pm

SIOUX FALLS, S.D.--(BUSINESS WIRE)--SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical development company advancing a new class of immunotherapies, today announced that it has entered into multiple collaboration and option agreements with global biotherapeutics leader CSL Behring. The collaborations will explore the possibility and the potential of new therapies to treat challenging autoimmune, infectious and idiopathic diseases by leveraging SABs DiversitAb platform.

SAB has developed a unique platform, through advanced genetic engineering, to naturally and rapidly produce large amounts of human antibodies without using human donors.

The agreement includes a research program which will investigate a potential new source for human immunoglobulin G (IgG). Human IgG is currently used for a number of immunological and neurological diseases including Primary Immunodeficiency, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Guillain-Barre Syndrome (GBS), Immune Thrombocytopenic Purpura (ITP), and Multifocal Motor Neuropathy (MMN).

CSL Behring is a leader in the global immunoglobulins market, which has grown substantially over the last five years. Key factors fueling market growth include an aging population, increased emphasis on the diagnosis and treatment of immune diseases, and its increased use in new indications.

SAB Biotherapeutics has developed a very interesting and novel platform for the production of human immunoglobulins, said Dr. Andrew Nash, Senior Vice President, Research for CSL Behring. CSL Behring is committed to the continuous development of innovative therapies that address unmet needs for patients with rare and serious diseases. This collaboration will provide both companies an opportunity to explore the potential of these new approaches to positively impact areas of need.

CSL Behrings R&D footprint includes more than 1,700 scientists across the globe with an R&D investment exceeding $800 million in 2018 - 2019.

We are excited that CSL Behring has chosen to work with SAB Biotherapeutics to explore new immunotherapies leveraging our technology platform, said Dr. Eddie J. Sullivan, president, CEO and co-founder of SAB Biotherapeutics. We believe combining our unique human antibody development and production capabilities with CSL Behrings established immunoglobulin franchise and vast expertise in biopharmaceutical development will broaden therapeutic possibilities.

CSL Behring and SAB will share research program and related costs and plan to complete the initial phase in 2020. The collaboration may lead to subsequent development and commercialization agreements.

About SAB Biotherapeutics, Inc.

SAB Biotherapeutics, Inc. (SAB), headquartered in Sioux Falls, S.D. is a clinical-stage, biopharmaceutical development company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies. Utilizing some of the most complex genetic engineering and antibody science in the world, SAB has developed the only platform that can rapidly produce natural, highly targeted, high-potency, immunotherapies at commercial scale. The company is advancing programs in autoimmunity, infectious diseases, inflammation and exploratory oncology.

Continue reading here:
SAB Biotherapeutics Announces Research Collaboration With CSL Behring - Business Wire

Read More...

Office of Technology Assessment: It’s time for a second coming | TheHill – The Hill

January 11th, 2020 5:49 pm

Congress must deal with a growing number of issues that new technological developments are forcing on the nation. I deliberately write forcing because the way technology works, no one asks the nation or its elected representatives if we need or want a given new technology. Any investor or engineer, these days more often a startup group or a tech corporation, can make the nation adapt to whatever they concoct.

For instance, a small group of young hotshot engineers is perfecting deep fake, a technology that enables one to make a video that will seem to be a very authentic presentation by a well-known politician, only it is completely made up. To consider the implications of this new gift to mankind, imagine that a day before the election, a candidate states that she has changed her mind and now favors something that will completely antagonize her base. By the time denials are issued and the truth comes out, the election may well be lost.

All of this does not point to the need for some licensing board to which technologists will have to apply before they can proceed but to a growing and urgent need for the nation to have the capacity to learn about new technological developments as early as possible, and prepare to deal with the consequences. And, possibly, in some rare cases well need to impose some restrictions on these developments.

Individual members of Congress and their staffs often do not have the resources, time or sufficient technical backgrounds to carry out such assessments. Hence the merit of recent moves to reestablish an Office of Technology Assessment (OTA) to play a major role in preparing technological assessments for Congress.

Last April Rep. Tim RyanTimothy (Tim) RyanOffice of Technology Assessment: It's time for a second coming Key moments in the 2020 Democratic presidential race so far GM among partners planning .3B battery plant in Ohio MORE (D-Ohio) included funding for OTA in a 2020 spending bill. But when the matter was discussed during a hearing of the House Committee on Science, Space and Technology in December, only a few members seemed to favor a full revival of the OTA.

The value of the defunct OTA is captured in an op-ed by Celia Wexler, the senior Washington representative at the Center for Science and Democracy. Wexler wrote:

The information they provided was used to make smart and applicable policy decisions. A 1984 study questioning the reliability of polygraph tests led Congress to enact limits on their use by employers. Another report from 1994 helped lawmakers assess the Social Security Administrations computer procurement plan, and ended up saving the government $368 million. OTA reports in 1987 and 1990, which concluded that Pap smears and mammograms for older women could save thousands of lives, were instrumental in extending Medicare reimbursement for these tests.

In 1972, Congress created the Office of Technology Assessment (OTA) to counsel senators and members of the House of Representatives on topics related to science and technology. Its ambitious goal was to give Congress technical expertise equal to that available to the executive branch through its many departments and agencies. The OTA board included representatives of both political parties and houses of Congress.

For over 20 years it produced approximately 750 reports dealing with issues raised by new technologies.

Congress defunded the OTA in 1995, keeping a promise that Rep. Newt GingrichNewton (Newt) Leroy GingrichMORE (R-Ga.) made during the successful Republican election campaign in 1994. Rep. Robert S. Walker (R-Pa.), who chaired the House Science Committee, disapproved of the OTA, argued that the pieces of legislation its reports were meant to inform often had to proceed without them due to the amount of time it took the OTA to produce a report.

The director of the agency acknowledged that it did not always finish reports in time to inform legislation. But he noted that agency researchers had testified about their work in progress at hearings and prepared less lengthy interim reports, when requested.

No single reason was given for the closing of the OTA. But some Republican lawmakers came to view it as duplicative, wasteful and biased against their party.

Another factor in the demise of OTA were, oddly, its neutrality. A former head of the OTA, Dr. John H. Gibbons, put it this way: If you belong to everyone, you belong to no one.

Another complaint was the dearth of public participation. Jathan Sadowski of the Consortium for Science, Policy & Outcomes at Arizona State University explained that [i]t did not adequately collect and examine the perspectives of a wider citizenryby, say, changing up their advisory panels or through methods like opinion polling and consensus conferences.

A major reason why the OTA must be revived is the accelerating pace of technological innovation, including in countries such as China. To illustrate, we need to assess the effect of AI (whether advanced in the U.S., China, Israel or elsewhere) on the destruction of jobs; the safety of driverless autos; the morality of the use of CRISPR for genetic engineering; facial recognition as a public safety tool; the impact of social media on democracy and society; and much more.

There seems to be ample work for at least one OTA. But it may well need to draw on the help of other organizations, such as the National Academy of Sciences, the NSF and DARPA.

Amitai Etzioni is a university professor and professor of international affairs at The George Washington University. Click here to watch a recent, four-minute video Political and Social Life after Trump. His latest book, Reclaiming Patriotism, was published by University of Virginia Press in 2019 and is available for download without charge.

View original post here:
Office of Technology Assessment: It's time for a second coming | TheHill - The Hill

Read More...

Poplar Trees Were Genetically Modified to Not Harm Air Quality Heres What Happened in Testing – SciTechDaily

January 11th, 2020 5:49 pm

The Oregon plantation in October 2014, the second year of growth. Credit: T. Rosenstiel, Portland State University

Field trials in the Northwest and Southwest show that poplar trees can be genetically modified to reduce negative impacts on air quality while leaving their growth potential virtually unchanged, says an Oregon State University researcher who collaborated on the study.

The findings, published today in the Proceedings of the National Academy of Sciences, are important because poplar plantations cover 9.4 million hectares globally more than double the land used 15 years ago. Poplars are fast-growing trees that are a source of biofuel and other products including paper, pallets, plywood and furniture frames.

A drawback of poplar plantations is that the trees are also a major producer of isoprene, the key component of natural rubber and a pre-pollutant.

The Arizona plantation in May 2013, during the first year of growth. Credit: D.J.P. Moore (University of Arizona)

Increases in isoprene negatively affect regional air quality and also unbalance the global energy budget by leading to higher levels of atmospheric aerosol production, more ozone in the air and longer methane life. Ozone and methane are greenhouse gases, and ozone is also a respiratory irritant.

Poplar and other trees including oak, eucalyptus, and conifers produce isoprene in their leaves in response to climate stress such as high temperatures.

A research collaboration led by scientists at the University of Arizona, the Institute of Biochemical Plant Pathology in Germany, Portland State University and OSU genetically modified poplars not to produce isoprene, then tested them in three-year trials at plantations in Oregon and Arizona.

They found that trees whose isoprene production was genetically suppressed did not suffer any ill effects in terms of photosynthesis or biomass production they were able to make fuel and grow as well as trees that were producing isoprene.

Steve Strauss, distinguished professor of forest biotechnology in the OSU College of Forestry, said there are a couple of possible explanations for the findings.

One is that, without the ability to produce isoprene, the modified poplars appear to be making compensatory protective compounds.

Another is that most of the trees growth takes place during cooler times of the year, so heat stress, which triggers isoprene production, likely has little effect on photosynthesis at that time.

Our findings suggest that isoprene emissions can be diminished without affecting biomass production in temperate forest plantations, Strauss said. Thats what we wanted to examine can you turn down isoprene production, and does it matter to biomass productivity and general plant health? It looks like it doesnt impair either significantly. In Arizona, where its super hot, if isoprene mattered to productivity, it would show up in a striking way, but it did not. Plants are smart theyll compensate and do something different if they need to.

Measurements being collected on a representative tree at the Arizona plantation, June 2013. Credit: D.J.P. Moore (University of Arizona)

In this study, scientists used a genetic engineering tool known as RNA interference. RNA, ribonucleic acid, transmits protein coding instructions from each cells DNA, deoxyribonucleic acid, which holds the organisms genetic code.

RNA interference is like a vaccination it triggers a natural and highly specific mechanism whereby specific targets are suppressed, be they the RNA of viruses or endogenous genes, Strauss said. You can also do this with CRISPR at the DNA level, and it usually works even better.

CRISPR, short for clustered regularly interspaced short palindromic repeats, targets specific stretches of genetic code for DNA editing at exact locations.

You could also do the same thing through conventional breeding, Strauss said. It would be a lot less efficient and precise, and it might be a nightmare for breeders who may need to reassess all of their germplasm and possibly exclude their most productive cultivars as a result, but it could be done.

Corresponding author Russ Monson of the University of Arizona said the study lays the groundwork for future isoprene research, including in different growing environments.

The fact that cultivars of poplar can be produced in a way that ameliorates atmospheric impacts without significantly reducing biomass production gives us a lot of optimism, Monson said. Were striving toward greater environmental sustainability while developing plantation-scale biomass sources that can serve as fossil fuel alternatives. We also need to keep working toward solutions to the current regulatory and market roadblocks that make large-scale research and commercial uses for genetically engineered trees difficult.

Sustainable forest management systems and their certifying bodies operate under the assumption that genetically modified equates to dangerous, Strauss said.

If something is GMO, its guilty until proven safe in the minds of many and in our regulations today, he said. These technologies are new tools that require scientific research to evaluate and refine them on a case-by-case basis. We have a huge need for expanded production of sustainable and renewable forest products and ecological services, and biotechnologies can help meet that need.

###

Reference: High productivity in hybrid-poplar plantations without isoprene emission to the atmosphere by Russell K. Monson, Barbro Winkler, Todd N. Rosenstiel, Katja Block, Juliane Merl-Pham, Steven H. Strauss, Kori Ault, Jason Maxfield, David J. P. Moore, Nicole A. Trahan, Amberly A. Neice, Ian Shiach, Greg A. Barron-Gafford, Peter Ibsen, Joel T. McCorkel, Jrg Bernhardt and Joerg-Peter Schnitzler, 6 January 2020, Proceedings of the National Academy of Sciences.DOI: 10.1073/pnas.1912327117

Scientists from the University of California, Riverside, NASAs Goddard Space Flight Center, and the Institute for Microbiology in Greifswald, Germany, also collaborated on the study.

The National Science Foundation, the German Ministry of Education and Research, Portland General Electric, the U.S. Department of Agriculture, Portland State University, Oregon State University and the state of Arizona supported this research.

Read the original here:
Poplar Trees Were Genetically Modified to Not Harm Air Quality Heres What Happened in Testing - SciTechDaily

Read More...

With $110M to add to the bankroll, Generation Bio sets its sights on engineering a revolution in the gene therapy field – Endpoints News

January 11th, 2020 5:49 pm

Whoever comes out on top of the current race to gain pioneering approvals for new AAV-delivered gene therapies will have to look over their shoulders to watch the next tech wave forming on the horizon for gene therapy 2.0.

One of those next-gen players, Generation Bio, just brought in $110 million of venture cash to cover the cost of the rest of their preclinical journey toward something completely new in the field. The latest round brings the biotech which now has about 80 staffers up to $235 million in total since its inception about 3 years ago. That will fuel the rest of its preclinical stage of development as it looks to break into human studies in the back half of 2021.

That kind of 4-plus year timeline before the first human dosing could test the endurance level of a venture player. But Generation CEO Geoff McDonough looks over the past 2 years advancing a new lipid nanoparticle delivery system for their closed-end DNA therapies working to the day when gene therapies can be produced and sold for far less than the $2 million-or-so price tag today and sees lots of fast-paced advances.

I think the reality is we didnt have an expectation at the outset (on timelines), McDonough tells me. Recognizing the novel work needed to build the platform, the investors knew it would take time and money to bring them up to a GMP level.

I would say for a 40-year problem, adds the CEO, 2 years seems pretty good.

The founding tech at Generation was designed to do what AAV treatments do in the nucleus, offering enduring expression, while allowing manufacturing at a biologic scale with a more economical, capsid-free production method. Taking a page from the tech handbooks at companies like Alnylam and Moderna, theyre building a gene therapy that they believe can do much better than the fragile, one-time-only pioneers. And without the $1 million production cost that keeps wholesale prices in the low 7-figure range.

Theyre looking for much greater economy, eventually taking these therapies to much broader ailments and out of the realm of rare diseases with a new approach that they believe can be infinitely redosable on an as-needed basis.

Thats the big picture.

Generations team is working on 2 lead programs for hemophilia A and phenylketonuria (PKU) to go into IND-enabling studies. Theyve now identified Wilson disease and Gaucher disease as likely starting points for the next steps as they move past the liver to skeletal muscle and the retina and then other tissues. And McDonough the former CEO at Sobi is looking down the road 12 to 18 months when hed like to turn to the public markets with an IPO to fund the first clinical-stage work.

In the meantime, hed like to concentrate on opening another new chapter of the company on the dealmaking side.

It felt very important not to partner initially, says McDonough. The investors wanted to retain ownership of platform. We just had tremendous good fortune we didnt need to do that for finance reasons. But now that they have a better grasp of the technology and what needs to be done, its time to partner probably later in the year.

T. Rowe Price funds and accounts led the round, with Farallon and Wellington Management Company jumping in alongside. Existing investors Atlas Venture, Fidelity, Invus, Casdin, Deerfield, Foresite Capital and an entity associated with SVB Leerink came back to stay in the syndicate. Cowen served as exclusive placement agent for the offering.

Read more:
With $110M to add to the bankroll, Generation Bio sets its sights on engineering a revolution in the gene therapy field - Endpoints News

Read More...

GM in India: Faking it on the Astroturf – Dissident Voice

January 11th, 2020 5:49 pm

According to arecent reportin The Hindu Business Line, Indias intelligence agencies are investigating the role of a global investment company and international seed companies in supporting farmers organisation Shetkari Sanghatana (SS) in the distribution of illegally procured genetically modified (GM) herbicide tolerant (HT) cotton seeds. The planting of such seeds is an offence under the Environment Protection Act and Seeds Act.

In May 2019, SS broke the law and freely distributed these seeds. In early January 2020, it broke the law again by distributing second generation seeds. According to the report, a senior intelligence official had toldBusiness Linethat a global investment company, with investments in seeds and agrochemicals companies, has chosen to support the farmers organisation.

Business Line reports that the investment company is allegedly putting pressure on the Modi government to ensure that the Genetic Engineering Appraisal Committee fast tracks the clearance of HT seeds, so the seeds could be legally harvested and sold in the country.

In India,five high-level reportshave advised against the adoption of GM crops. Appointed by the Supreme Court, the Technical Expert Committee (TEC) Final Report (2013) was scathing about the prevailing regulatory system and highlighted its inadequacies and serious inherent conflicts of interest. The TEC recommended a 10-year moratorium on the commercial release of all GM crops.

The reason why Bt cotton to date, Indias only officially approved GM crop made it into farmers fields in the first place was due to approval by contamination. Bt cotton was discovered in 2001 growing on thousands of hectares in Gujarat. In March 2002, it was approved for commercial cultivation.

The pro-GMO lobby has again resorted to such tactics. The 2010 moratorium on Bt brinjal was implemented because science won out against a regulatory process that lacked competency, possessed endemic conflicts of interest and demonstrated a lack of expertise in GM risk assessment protocols, including food safety assessment and the assessment of environmental impacts.

As we have seen with the relentless push to get GM mustard commercialised, the problems persist. Now, to justify breaking the law, we are seeing unscientific claims and well-worn industry-inspired soundbites about GM crops: political posturing unsupported by evidence to try to sway the policy agenda in favour of GM.

Drawing on previous peer-reviewed evidence, a2018 paperin the journal Current Science by renowned scientists PC Kesavan and MS Swaminathan concluded that Bt crops and HT crops are unsustainable and globally have not decreased the need for toxic chemical pesticides, the reason for these GM crops in the first place.

We need to look at GM objectively becauseplenty of evidenceindicates it poses risks or is not beneficial and that non-GM alternatives are a better option. Moreover, many things that scientists are trying to achieve with GM have already beensurpassed by means of conventional breeding.

Those behind the distribution and planting of illegal seeds talk about helping the farmer. But the real agenda is to open-up India to GM and get farmers hooked on a corporate money-spinning GM seed-chemical treadmill.

The watchdog GMWatch recently produced an article about how hired public relations agencies and key individuals with firm links to the biotechnology sector are attempting to deceive the public and policy makers. The articles author, Jonathan Matthews, notes that in June 2019 the pro-GMO campaignerMark Lynasbegantalking upwhat heclaimedwas to be the worlds first pro-GMO protest.

The term astroturfing is the process by which orchestrated marketing and public relations campaigns are presented as emanating from grassroots participants or ordinary members of the public rather than from powerful corporate interests.Lynas, a well-known industry lobbyist, said the protest would involve Indian farmers planting banned GM seeds in what hecalledGandhi-style civil disobedience. This attention-grabbing campaign was being led by SS, which Lynasdescribedas very grass roots.

According to Matthews, SS is not a mass movement of grassroots farmers but an allegedlywell-fundedfringe group created by the lateSharad Joshi, a right-wing economist andmemberof the Advisory Board of the Monsanto-backedWorld Agricultural Forum, an organisation whose founder and first chairman was for many years Monsantos director of public policy.

Joshi was also Chairman of Shivar Agroproducts Ltd, says Matthews, but he is best remembered for his ultra-libertarian ideology, his links to certain farmers groupsand the political party (Swatantra Bharat Paksh) that he founded all vehicles for promoting his free market fundamentalism.

Matthews says:

Lynas was not the first to present Shetkari Sanghatana as representing ordinary Indian farmers. A full two decades earlier, the European biotech industry and their PR firm Burson-Marsteller brought some of Shetkari Sanghatanas leading lights to Europe to try and counter the view that Indian farmers opposed GMO crops. To that end, they were toured around five different countries by the industrys lobby group, EuropaBio, which in a press releasepresented this free market fringe group, which islargelyconfined to the state of Maharashtra, as the mainstream farmers movement in India.

Matthews adds that the US is the biotech industrys chief propaganda hub for promoting wide-ranging fakery to the world. Referring to the illegal planting of HT cotton seeds and SS, he says:

Among the notable cheerleaders promoting the protesters cause were the Gates-backed GMO propaganda outfit The Alliance for Science, which paysMark Lynasto lobby for GMOs;CS PrakashofAgBioWorld, who has long served as a conduit forMonsanto disinformation;Bayer-consultantandMonsanto collaboratorKevin Folta, who made apodcaston the protests withCS Prakash

Matthews piece, Fake Farmer Willi part of an international fake parade, provides details of the various characters and strategies involved in faking it for the biotech industry, not just in India but across the world.

As a market for GM proprietary seeds, chemical inputs and agricultural technology and machinery, India is vast. The potential market for herbicide growth alone, for instance, is huge: sales could now have reached USD 800 million with scope for even greater expansion, especially with the illegal push to get HT seeds planted.

With GM crops largely shut out of Europe and many countries reluctant to embrace the technology, Western agro-biotech conglomerates are desperate to seek out and expand into untapped (foreign) markets to maintain profitability.India presents potential rich pickings. And this is the bottom line: GM is not about helping farmers or feeding the masses (myths that have been deconstructed time and again). It is about hard-nose interests endeavouring to displace existing systems of production and capturing and exploiting markets by any means possible not least fakery and deception.

This article was posted on Friday, January 10th, 2020 at 7:15pm and is filed under GMO, India.

Link:
GM in India: Faking it on the Astroturf - Dissident Voice

Read More...

As the planet warms, unusual crops could become climate saviors if we’re willing to eat them – GreenBiz

January 11th, 2020 5:49 pm

This article originally appeared in Ensia.

In southern Israels stifling heat, rows of salicornia, commonly known as sea asparagus or sea beans, grow under translucent tarps, planted into ground more sand than soil, irrigated with saltwater. This environment would kill most plants, but these segmented succulents look beautiful green and healthy. In partnership with researchers at Ben Gurion University of the Negev, local farmers are exporting them to markets in nearby countries.

Sea beans taste like salty cucumber and grow wild in coastal areas around the globe. But in recent years researchers have begun to focus on them for agriculture, especially in dry coastal regions such as India, Israel, Turkey and the United Arab Emirates. These researchers efforts are defining what extremes the plant can withstand, its nutrient needs and how to get it to grow faster and with greater yield. As the planet warms and the seas rise, resilient crops such as sea beans might become climate saviors. But only if we are willing to eat them.

Everybody matters

Climate change is already affecting our food supply. In a paper published this year,researchers calculatedthat the available calories from the worlds top 10 food crops were 1 percent less annually than they would have been without the impact of climate change. Surveys show the potential for drought tops peoples climate concerns worldwide, but when it comes to growing crops, says Hope Michelson, an assistant professor of agriculture and consumer economics at University of Illinois at Urbana-Champaign, "its not just the amount of rain" that matters. Crops are also sensitive to variations in how quickly that rain falls, high and low temperature extremes, the frequency and intensity of storms and the length and timing of growing periods.

Food crops that can withstand such conditions will be increasingly important, and much discussion around climate-friendly food focuses on consumer choices and what they mean for broader adoption of these crops. Essentially, there has to be a market for climate-resilient foods to have a significant impact. Consumers can vote with purchasing dollars to support farmers who grow foods that will persist in difficult conditions, and those that require fewer resources.

But outside factors, the food and beverage industries among them, exert influence over our choices. While data on adults is mixed, research shows that food marketing strongly influences children. A 2009 article in the Annual Review of Public Health found evidence "that television food advertising increases childrens preferences for the foods advertised and their requests to parents for those foods." A more recent look at the data in The American Journal of Clinical Nutrition concluded, "Evidence to date shows that acute exposure to food advertising increases food intake in children but not in adults."

Essentially, there has to be a market for climate-resilient foods to have a significant impact. Consumers can vote with purchasing dollars.

Still, while most researchers recognize the importance of large-scale actions, such as those by large companies and government regulations, to influence the food system, many emphasize that individual food choices also can have an impact.

"You can most definitely make a movement with your pocketbook," says Samantha Mosier, an assistant professor in the political science department at East Carolina University. She points to trends in soda consumption, which has declined significantly in recent years. "Some of this has been brought on by the millennial generation trying to be healthier and to avoid some of the pitfalls of our older generation," Mosier says. Soda giants Coca-Cola and Pepsi areinvesting in lower sugar options such as kombucha, coconut water and sparkling water.

"When you think about land use and the predictions for climate change, much of it depends on consumer preferences," says Christine Foyer, a professor of plant sciences at University of Birmingham in the United Kingdom. "People decide what they eat, and economics drives the crops which drives the science. Everybody matters."

Climate-resilient plants

Environmentally sensitive eating often focuses on reducing meat consumption, and for good reason. "The environmental cost particularly of beef is enormous," Foyer says. Last year in the journal Science, researchers estimated that globally, "[m]oving from current diets to a diet that excludes animal products has transformative potential, reducing foods land use by (7.7 billion acres)" and greenhouse gas emissions by about 7.3 billion tons.

But plant-based choices matter too.

In the future, plants ability to withstand extreme conditions will become critical. Scientists are working to increase hardiness in todays staple crops such as wheat and corn through gene editing, genetic engineering and traditional breeding to increase the efficiency of photosynthesis, reduce water requirements and resist pests. In China, for example, researchers have used CRISPR to develop a strain of wheat that resists powdery mildew, a damaging fungal growth predicted to worsen with climate change. Meanwhile in India, the International Crops Research Institute for Semi-Arid Tropics (ICRISAT) developed early-maturing groundnuts to help farmers harvest before drought. Farmers who adopted these varietals earned an additional $119 per 2.5 acres, according to the organization.

Scientists are working to increase hardiness in todays staple crops such as wheat and corn ... to increase the efficiency of photosynthesis, reduce water requirements and resist pests.

Foyer also points to legumes and pulses which include fava beans, cowpeas, chickpeas and lentils because "they have their own nitrogen fertilization," reducing the need for fertilizers. Nitrogen-based fertilizers require energy to produce, can cause pollution and marine die-off when runoff enters streams and waterways, and may contribute to global warming as source of greenhouse gas emissions.

Yet another climate-friendly option is sea vegetables. Seaweeds such as kelp are farming powerhouses: high nutrition value; fast growing; and zero land use for growing. Not only that, but "when you grow kelp, youre growing it in ocean water and [the kelp is] absorbing carbon dioxide," Wheat says. "And when you suck up that carbon dioxide, you also change the pH and reduce the consequences of ocean acidification."

Changes require work

Not all climate-resilient foods are new and unusual. Okra, mushrooms, sweet potatoes and pomegranates are all resilient choices in many regions. So, too are edible "weeds"such as dandelion and burdock, which are hardy enough to survive our efforts to eliminate them. Yet as warming gets more extreme, researchers say we may have to adopt less familiar foods.

For many people, that wont be easy. What we eat has deep cultural significance, rich in memories and meaning. We cling to what we know, and changes require work. Then there are economic considerations, says Mosier. When people are concerned about the economy, food choices based on environmental impacts can take a back seat to simply putting enough food on the table.

Some recent examples point to how changing diets isnt impossible. Quinoa and the Impossible Burger, a plant-based burger masquerading as beef, are two recent success stories that at first seemed unlikely to win over U.S. consumers. The Chicago Tribune reported in 2016, "Americans consume more than half the global production of quinoa, which totaled [34,000 metric tons] in 2012. Twenty years earlier, production was merely [544 metric tons]." The Impossible Burger, although it makes up a small percentage of the U.S. meat market, is for sale in more than 15,000 restaurants in the United States, Hong Kong, Macau and Singapore. It has been so popular that the company experienced a production shortage last summer, soon after announcing a partnership with Burger King. Production has caught up with the surging demand, and diners can find Impossible meat at White Castle, Red Robin and a host of smaller restaurants, as well as at grocery stores.

These foods owe their rise in large part to marketing and lobbying dollars, but there are other ways to find success. Anastasia Bodnar, policy director of Biology Fortified, a nonprofit organization focusing on issues in agriculture and biotechnology, says that chefs and restaurants also can have an impact on how people think about food.

"If you can make it cool, make it sexy, make it something that people want to see, thats going to end up in the news, then that interest gets perked up and then the market goes along with it," Bodnar says. "You see all kinds of weird invasive fish on menus that have been rebranded with different names."

If you can make it cool, make it sexy, make it something that people want to see, thats going to end up in the news, then that interest gets perked up and then the market goes along with it.

Whether familiar or foreign, our food crops will need to feed an increasing number of people in an increasingly hostile environment in the future. While structural, top-down change may be necessary to shift the entire food system to one that will weather the effects of climate disruption, such changes can be influenced by individual choices.

Back in Israel, on farms in the dry and salty desert, sea beans grow green in seawater. In India, rows of millet persist through drought. And in the frigid but warming waters around Seattle, kelp forests undulate with the tides. Such foods reduce pressure for climate-unfriendly land use change and thrive in environments that make other plants shrivel. That is, they are suited for the future which means we, too, can be more resilient to change.

Editors note: Jenny Morbers travel and access to researchers at Israels Ben Gurion University of the Negev was paid for and provided by the Murray Fromson Journalism Fellowship.

See the article here:
As the planet warms, unusual crops could become climate saviors if we're willing to eat them - GreenBiz

Read More...

Page 730«..1020..729730731732..740750..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick